A LETTER TO THE SHAREHOLDERS OF BRISTOL-MYERS SQUIBB COMPANY

February 28, 2019

Dear Fellow Shareholders,

Starboard Value LP (together with its affiliates, “Starboard”) is a shareholder of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”). We are writing today as we believe that Bristol-Myers is deeply undervalued and the recent announcement of the Company’s proposed acquisition of Celgene Corporation (“Celgene”) is poorly conceived and ill-advised. We intend to vote all of our shares against the proposals related to the proposed acquisition, and, should the transaction be voted down by shareholders at the Company’s upcoming Special Meeting of Shareholders scheduled to be held on April 12, 2019 (the “Special Meeting”), we have also nominated a slate of director candidates who we would seek to elect at the 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) to ensure that the Board is held accountable and that the Company focuses on exploring and executing on the best alternative for value creation at Bristol-Myers.

Additionally, under separate cover, we will be delivering to Bristol-Myers a books and records demand under Delaware law requesting that they provide us with information that will allow us to further investigate the facts and circumstances leading up to, and including, the process and diligence that led to the proposed acquisition of Celgene.

As you know, Starboard is an investment management firm that seeks to identify and execute on opportunities to unlock value in its portfolio companies for the benefit of all shareholders. We have a long and successful history as shareholder advocates, working constructively with companies to drive long-term value creation through a combination of strategic refocusing, improved operational execution, more efficient capital allocation, and stronger management discipline.

We have followed both Bristol-Myers and Celgene for a long time; thus we are well aware of their respective publicly-stated strategic ambitions and long-term strategies. Therefore, we, like many Bristol-Myers shareholders, were extremely surprised when the Company announced its intention to acquire Celgene for approximately $91 billion, through a combination of cash and stock, representing one of the largest ever pharmaceutical mergers.

This announcement follows years of poor financial and stock price performance at Bristol-Myers. As shown in the chart below, the Company has underperformed its direct peers over almost any time frame.
These results are not reflective of a management team and Board of Directors that has earned the right, in our view, to execute on a “bet the company” acquisition. We believe the risks inherent in this acquisition paired with the long-term poor results at Bristol-Myers make it untenable to support such a transaction. Accordingly, we will be filing preliminary proxy materials in the coming days in order to solicit Bristol-Myers’ shareholders to vote against the share issuance proposal in connection with the proposed acquisition at the upcoming Special Meeting.

The actions we are taking – specifically, our intent to solicit shareholders to block the proposed acquisition of Celgene – are not taken lightly. We are doing so because we strongly believe that the proposed deal is not in the best interest of shareholders. This view has been solidified by the numerous other large, long-term shareholders who appear to likewise believe this deal is not in the best interest of shareholders.

We have rigorously studied the proposed transaction since its announcement in early January in order to better understand the perspectives of all parties involved. We have done extensive work, including independent research as well as numerous meetings and phone calls with Bristol-Myers management, in an attempt to understand the strategic and financial benefits of the proposed transaction. We have approached our work with an open mind and a willingness to be convinced that this proposed transaction actually makes good financial and strategic sense. Unfortunately, the more work we do, the more conviction we build that this transaction is not in the best interest of shareholders. Therefore, we intend to solicit shareholders to vote against the transaction.

As we summarize in this letter to shareholders, our conclusion is based on five primary views:

1) Bristol-Myers is buying a company with a massive patent cliff – among the largest in pharmaceutical industry history – which will serve as a major overhang on the Company’s shares in the years to come. As demonstrated in our analysis below, the patent cliff caused by REVLIMID alone will require Celgene to replace over 60% of its total revenue in the next 7 years. This type of accomplishment is mostly unprecedented.
2) Our belief is that the Celgene pipeline is extremely risky and will continue to require significant research & development (“R&D”) funding. Bristol-Myers management’s projections contemplate Celgene essentially rebuilding its entire current revenue base from its pipeline over the next 8 years, as essentially all of Celgene’s marketed products lose patent protection over this timeframe. We believe this is an aggressive assumption and may not be realistic based on historical precedents.

3) The process and diligence timelines leading up to the announcement of the acquisition, as outlined in the Company’s S-4, lead us to believe that this transaction was hastily construed and perhaps done to thwart potential strategic interest in Bristol-Myers. We believe that if the Company remains independent, it is quite possible that there may be strategic interest in Bristol-Myers at a substantial premium to the current stock price.

4) We believe Bristol-Myers’ analysis of the financial merits of the transaction – specifically its allocation of value between Celgene’s marketed products, the combined synergies, and the Celgene pipeline – is potentially misleading based on our diligence.

5) There is a better path forward for Bristol-Myers, either as a more profitable standalone company with a more focused, lower-risk strategy, or in a potential sale of the whole Company.

In the following pages, we delve into greater detail on our primary points. Over the next few weeks, we intend to share a detailed presentation well in advance of the shareholder vote on April 12th. We look forward to engaging with our fellow shareholders and appreciate your consideration of our views.

**Bristol-Myers is acquiring one of the largest patent cliffs in the history of the pharmaceutical industry.**

Historically, pharmaceutical companies have made large acquisitions to fill gaps in their product portfolio and avoid potential patent cliffs. As biosimilars have only recently entered the pharmaceutical markets, historically patent cliffs were caused exclusively by small molecule drugs. Typically, genericization of a small molecule drug would occur rapidly, resulting in substantial revenue decline for the innovator drug. However, thus far, large molecule biologics have proven to be much more durable than small molecule drugs. As shown in the chart below, revenue erosion for large molecule drugs post-loss-of-exclusivity (“LOE”) is significantly slower than that of small molecule drugs, which are easier to replicate and often experience dramatic sales declines within the first year of LOE.
It is important to note the differences between large and small molecule drugs in terms of historical genericization because they make the proposed transaction extremely puzzling. In short, Bristol-Myers is knowingly acquiring a massive small-molecule patent cliff. This is, to our knowledge, unprecedented, certainly to this scale. Celgene’s key product, REVLIMID, a small molecule drug that generated approximately $9.7 billion in worldwide sales in 2018 (>60% of Celgene’s total revenues), is expected to face generic competition beginning in 2022. In addition, given the rarity of such a high revenue generating small molecule drug, this represents a potentially massive opportunity for generic manufacturers. As such, numerous manufacturers are attempting to bring generic REVLIMID to market, which increases the risk that the drug faces generic competition before 2022 and/or the revenue decline is more dramatic once generic competition begins. In fact, just recently, Alvogen launched generic REVLIMID in certain European markets and expects a global launch this year.

Unlike Celgene, we believe that Bristol-Myers possesses a much more durable product portfolio. As shown below, with the exception of ELIQUIS, essentially all of the Company’s other marketed products are large molecule biologics. As a result, we believe the revenue decline for Bristol-Myers’ marketed products in the back-half of the next decade will be much less pronounced than peers that have a high proportion of small molecule products.
We do not believe that the REVLIMID generic risk can be understated. Based on our discussions with Bristol-Myers’ management team, we understand that their base-case scenario is a decline in REVLIMID revenues of approximately 90% in 2026. We believe that Celgene management is desperately trying to settle certain patent disputes with other generic manufacturers in an effort to bring more certainty to the near-term REVLIMID revenue projections. However, this does not change the fact that Bristol-Myers is knowingly acquiring a massive patent cliff with significant deal value concentrated in the net present value of the cash flows from one product. Acquiring such a patent cliff is highly unusual and unprecedented. We believe that, were shareholders to approve the transaction, this impending patent cliff will continue to be a massive overhang on Bristol-Myers shares – much like it has been for Celgene shares – for the foreseeable future.
Furthermore, this may create additional pressure for the combined company to consummate another large transaction to fill the impending revenue hole, as the reality of full REVLIMID genericization comes into focus.

Loss of Exclusivity / Patent Expiration for Bristol + Celgene’s Major Marketed Products\(^{(1)}\)

With only several weeks of full data room access, it appears Bristol-Myers estimated that Celgene will rebuild its entire current revenue base from its current pipeline despite several recent development miscues.

Per the Company’s S-4 filing, Bristol-Myers management is assuming Celgene can generate base-case, risk-adjusted revenues of nearly $19 billion by 2028. However, given the known patent cliff on Celgene’s marketed products, we believe that over 90% of this revenue, or approximately $17 billion is expected to come from yet un-commercialized pipeline products. In other words, Bristol-Myers management is asking its shareholders to believe that Celgene can essentially rebuild its entire current revenue base from its current product pipeline. That puts an immense amount of pressure on the pipeline to perform at an extraordinarily high level, one that we believe may be exceedingly difficult to meet, especially when the task is to replace one of the top selling global drugs.

As shown in the chart below, it is common to see blockbuster drugs representing approximately 15-30% of total company revenue at LOE, but REVLIMID at 63% of revenue at LOE is essentially unheard of and poses tremendous risk.

Source: Company Filings.

\(^{(1)}\) Loss of exclusivity and patent expirations shown are for U.S., with the exception of REVLIMID. Celgene’s settlement with Natco Pharma will allow Natco to manufacture and sell a genericized REVLIMID without volume restrictions beginning in 2026. As a result, we have shown Celgene losing REVLIMID revenues in 2026 even though U.S. patent expiration is in 2027.
Based on our analysis of the Celgene pipeline, we believe that Bristol-Myers’ projections are extremely optimistic, especially given the most recent developments. Based on our conversations with Bristol-Myers management, we believe that the Company is attributing 60% of 2028 pipeline revenues to five near-term product launch opportunities (i.e. luspatercept, JCAR017, bb2121, fedratinib, and ozanimod), with the remainder of revenues generated by ~20 earlier-stage assets, of which greater than 60% of indications are still in Phase I development.

Not surprisingly, sell-side analyst revenue projections for each of the five near-term products reveal wildly differing outlooks. In fact, as shown below, there is a $7.3 billion difference between the minimum and maximum cumulative 2028 revenue estimates for these five products.
However, Bristol-Myers management estimates for the five near-term product launch opportunities approximate the maximum of Wall Street analyst estimates.

<table>
<thead>
<tr>
<th>‘19 – ‘28 Wall Street Maximum Est. for Celgene Near-Term Launch Pipeline Products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated Bristol-Myers Management Base Case</strong>(1)</td>
</tr>
<tr>
<td>Fedratinib</td>
</tr>
<tr>
<td>bb2121</td>
</tr>
<tr>
<td>Luspatercept</td>
</tr>
<tr>
<td>JCAR017</td>
</tr>
<tr>
<td>Ozanimod</td>
</tr>
<tr>
<td>Min of Wall Street Estimates</td>
</tr>
<tr>
<td>(1) Estimated based on S-4 disclosure of Bristol-Myers’ Celgene estimates and discussion with Company management.</td>
</tr>
</tbody>
</table>

Based on Celgene’s most recent track record of overpromising and under-delivering on highly-touted pipeline products – specifically, the termination of GED-0301 and the refusal-to-file (“RTF”) for ozanimod – we question whether management’s projections are sufficiently conservative.

Select Celgene Management Commentary on GED-0301 and ozanimod

**7-months before termination of GED-0301**

“And then you have ozanimod, GED-0301. Both of those – as I mentioned before, ozanimod is a $4 billion to $6 billion asset. **GED-0301 for Crohn’s disease could be transformational as well. In our opinion, it’s probably a multi-billion dollar asset as well.**”

*Patrick Flanigan, Corporate VP – Investor Relations*  
*March 2017*

**1-month before receiving refusal-to-file notice from FDA on ozanimod**

“Focusing on execution, the NDA for ozanimod in RMS was submitted on the heels of two positive global Phase III studies. **We are currently building out a strong neuro-inflammation team to execute a launch and unlock the value of this important product.**”

*Scott Smith, President & COO*  
*January 2018*

Source: Company Filings and Transcripts.
For example, Chimeric Antigen Receptor T-cell (“CAR-T”) therapies, which account for two of the five near-term product launch opportunities, are prime examples of a category where sell-side revenue estimates have massively declined since the drugs have come to market. The two current commercialized drugs, Gilead’s YESCARTA and Novartis’ KYMIRAH, have experienced declining revenue estimates due to issues around safety, cost, logistics, and insurance reimbursement.

2022 Wall Street Revenue Estimates For Approved CAR-T

![Graph showing revenue estimates for approved CAR-T therapies](image)


While Celgene management has argued that JCAR017 and bb2121 have demonstrated a superior safety profile in early-stage trials, their recent commentary on timelines for approval has become more measured.

Timeline of Celgene Management Commentary on JCAR017 (i.e. liso-cel)

- **“We anticipate JCAR017’s first approval in 2019 and for that therapy to achieve global peak sales of approximately $3 billion”**
  - Peter Kellogg, EVP, CFO, CAO
  - January 2018

- **“So the approval for JCAR017 liso-cel is 2019, that’s still the plan.”**
  - Nadim Ahmed, Pres. of Hematology & Oncology
  - June 2018

- **“Now turning to our CAR-T programs. Both liso-cel and bb2121 remain on target for expected 2020 approvals.”**
  - Jay Backstrom, Chief Medical Officer
  - January 2019

- **“Just the expected launches of fedratinib and JCAR017 in 2019 will enable us to absorb the financial impact caused by the delay in the expected launch of ozanimod.”**
  - Mark Alles, Chairman & CEO
  - May 2018

- **“Well, for JCAR017…Investors should not expect new data… ASH will not be updated data for 17 on lymphoma.”**
  - Mark Alles, Chairman & CEO
  - September 2018

Source: Company Filings and Transcripts.
Based on the tepid uptake of current marketed CAR-T therapies, and the fact that Celgene’s CAR-T therapies will be much later to market than the current approved therapies, we believe their potential to be blockbuster drugs is far from certain.

For the early Celgene pipeline, details are limited. However, it is important to note that according to Bristol-Myers 10-K disclosures, 92% of Phase I studies fail to reach FDA approval. Assuming similar rates of approval going forward, this means that only 2-3 of Celgene’s early-stage assets will receive FDA approval. Given that we believe Bristol-Myers is assuming that approximately 40% of 2028 Celgene pipeline revenues, or approximately $7 billion, will be generated from pipelines assets outside of the five near-term product launch opportunities, it appears that they are assuming multiple blockbuster assets. Based on historical precedent, we would have serious questions on this assumption.

It is imperative to point out that in a downside scenario, we believe Celgene’s pipeline products could destroy significant shareholder value. Each product requires tremendous upfront investment, and if it does not perform in-line with expectations, the product can generate a negative net present value. For example, Celgene has not brought a new major drug to market since 2014. However, since that time, the Company has spent a cumulative $22 billion on R&D. So in approximately the past five years, Celgene has failed to bring a single new major drug to market. However, Bristol-Myers is now assuming that going forward, the Celgene pipeline will produce a number of new major drugs at a much faster rate than previously achieved.

Furthermore, the diligence timeline appears extremely troubling, especially as it relates to Bristol-Myers’ analysis of the Celgene pipeline. According to the Company’s S-4, full data room access was granted on December 16, 2018. Therefore, Bristol-Myers had only slightly more than two weeks of full access before announcing the transaction. We find it difficult to believe that the Company was able to thoroughly evaluate approximately 30 highly technical products with the required scrutiny on regulatory, commercial, manufacturing, intellectual property (“IP”), and legal considerations, among others, during this extremely tight timeframe. As a result, we have extreme doubts that Celgene’s pipeline can and will deliver the required results to fully rebuild the revenue base upon the LOE of REVLIMID.

We have serious concerns about the diligence process and motivations for the acquisition of Celgene.

Given the transformative nature of this transaction, we would have expected Bristol-Myers to undertake an exhaustive due diligence process on Celgene, as well as a robust analysis of all available alternatives for Bristol-Myers shareholder value creation. Unfortunately, based on the timeline in the S-4, while the Company did exchange some preliminary diligence materials prior to December 2018, it appears that the Company only had two weeks of full data room access prior to announcing the proposed acquisition and no such exploration of alternatives was ever contemplated.

As shown in the annotated stock chart below, it appears that after a failed clinical trial of a major drug that resulted in approximately $25 billion of lost market value, Bristol-Myers became the subject of not one, but two separate shareholder activists, who were, among other things, rumored
to be pressing for the Company to explore a sale. It seems that following these challenging times, Bristol-Myers began exploring a “bet the company” acquisition which would create such a large combined entity that any acquisition of the pro forma company would become exceedingly difficult. Nowhere in the disclosure related to the Celgene discussions, is there any mention of the idea that, before executing an acquisition of this scale, Bristol-Myers, itself, explored and more fully evaluated all strategic options to maximize value for shareholders. It therefore seems appropriate to conclude that a primary reason this transaction was pursued by Bristol-Myers was for defensive purposes.

In fact, Bristol-Myers has been rumored as a potential acquisition target for years. As shown below, many articles were published speculating that the Company was the subject of takeover interest.
While these rumors have yet to amount to anything substantive, we find the timing of management’s initial approach to Celgene curious. A casual observer might reasonably suspect that Bristol-Myers initiated merger discussions with Celgene in order to avoid shareholder pressure for the Company to conduct a sale process. Bristol-Myers is a premier asset in oncology, one of the most sought after therapeutic categories. This is an enviable position that we believe would garner a premium valuation if the Company were to conduct a full sale process. While we are not solely advocating for a sale of the Company, we strongly believe that management and the Board should be open to any option that maximizes value for shareholders.

There is a better path forward for Bristol-Myers.

Bristol-Myers is a leader in immuno-oncology. The Company possesses a number of innovative assets that have pushed the boundaries of science in order to save lives. Bristol-Myers has been at the leading edge of developing immuno-oncology drugs and in the recent past has spent a higher percentage of revenue on R&D than any other major pharmaceutical company. In fact, as shown in the chart below, over the past 5 years, on average, the Company has spent almost double the percentage of revenue on R&D as peers.

Management has assured shareholders that the Company continues to be well-positioned for both the short and long-term. In fact, earlier this year, management referred to the Company’s pipeline as “one of the most promising in our history” and has frequently commented on the progress of its pipeline.

![5-Year Average R&D Expense as % of Revenue](chart)

Source: Company Filings, CapitalIQ.

(1) Average of annual reported financials from 2014 – 2018. Peers based on Bristol-Myers S-4 selected publicly traded companies.
Unfortunately, R&D failures continue to plague the Company and have destroyed significant shareholder value in the process. Over the past five years, the Company has underperformed peers and the broader market index by approximately 40%.

The past year has been particularly painful for Bristol-Myers shareholders, as key clinical trials have failed to show the desired results and the Company’s future growth trajectory has been called into question.
The persistent challenges surrounding OPDIVO’s never-ending quest for first-line (“1L”) approval in non-small cell lung cancer (“NSCLC”) has been particularly frustrating. Despite initially securing a sizeable market share advantage in the NSCLC market with OPDIVO, the Company has seen recent trial failures potentially impair peak revenue potential, and, in the process, has likely ceded future leadership to Merck’s KEYTRUDA.

As a result, Bristol-Myers’ P/E ratio is now at its lowest level in years and below its peer group, despite a growing franchise and a net cash balance sheet.
We believe that there is significant room for improvement in Bristol-Myers’ margins. As previously mentioned, the Company’s R&D as a percentage of revenue is the highest of its peers, resulting in EBITDA margins well below average. As shown in the chart below, Bristol-Myers is currently producing EBITDA margins well below the peer average.

![FY2018 EBITDA Margins – Bristol vs. Peers](image)

Source: Company Filings, CapitalIQ.
(1) Peers based on Bristol-Myers S-4 selected publicly traded companies.

While cost cutting and margin improvement is one alternative that we believe is readily available to Bristol-Myers as a standalone entity, the Company’s Board should be open to evaluating all alternatives to create shareholder value, including a sale of the Company. If Bristol-Myers is focused on a potential revenue cliff in its product portfolio, those cliffs can be filled with targeted tuck-in acquisitions, or, alternatively, the Company can become a target for another company to further fill out their product portfolio.

We definitively believe the acquisition of Celgene is not in the best interest of Bristol-Myers shareholders.

Based on our analysis, we do not believe that the acquisition of Celgene is in the best interest of Bristol-Myers shareholders. This letter is focused on summarizing the key questions and concerns that have informed our views. We look forward to sharing a more detailed presentation of our views in the near future as we approach the shareholder vote.

The first crucial step in this campaign is to vote down this ill-advised transaction. It is important, however, for shareholders to also know that as the next step, we would seek shareholder support to elect a slate of highly-experienced and respected director candidates whom we have nominated for election at the 2019 Annual Meeting. We believe these steps, taken together, represent an exciting opportunity for shareholders to have a direct voice in protecting the value of their investment in the Company while ensuring that management and the Board are held accountable and re-focused on exploring the best alternatives available for maximizing shareholder value.

We look forward to continuing our dialogue with shareholders.
Best Regards,

[Signature]

Jeffrey C. Smith
Managing Member
Starboard Value LP